Pasithea Therapeutics Receives Nasdaq Delisting Notice for Minimum Bid Price Non-Compliance

summarizeSummary

Pasithea Therapeutics Corp. received a Nasdaq notice for failing to meet the $1.00 minimum bid price requirement, initiating a 180-day period to regain compliance.

check_boxKey Events · Corporate Governance and Compliance · KTTA

• Nasdaq Delisting Notice Received

  Pasithea Therapeutics Corp. received a notice from Nasdaq for non-compliance with the $1.00 minimum bid price rule, based on its stock trading below this threshold for 30 consecutive business days.

• 180-Day Compliance Period Initiated

  The company has 180 calendar days, until August 19, 2026, to regain compliance by having its common stock close at or above $1.00 for at least ten consecutive business days.

• Potential Reverse Stock Split

  The filing notes that a reverse stock split is a potential strategy to cure the deficiency, which follows the company's recent shareholder approval on January 28, 2026, to significantly increase authorized common stock.

auto_awesomeAnalysis · KTTA · Life Sciences

Pasithea Therapeutics Corp., a micro-cap company, has received a critical notice from Nasdaq for failing to maintain the $1.00 minimum bid price. This triggers a 180-day compliance period, during which the company must achieve a closing bid price of $1.00 or more for ten consecutive business days to avoid potential delisting. While not immediate, this notice signals significant market underperformance and poses a threat to the company's public listing, which is crucial for capital access and investor visibility, especially for a small company. The filing mentions a reverse stock split as a potential cure, which aligns with the recent shareholder approval to increase authorized common stock on January 28, 2026, suggesting the company may have been anticipating this situation. Investors should monitor the company's plan to regain compliance and the stock's performance closely.